Rimteravimab

瑞特韦单抗

Report date: 2022/04/17 20:00:41

Base Information

Drug NameRimteravimab
Drug Alias NameVHH SARS-COV-2 THERAPY - ExeVir BioVHH72-FcXVR-011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumItalyMoldova, Republic of
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExeVir Bio
China Registration ClassN/A

Develop Information

Active CompaniesMithra Pharmaceuticals SAExeVir Bio
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A